Market Research Logo

Melanoma - Pipeline Review, H1 2018

Melanoma - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Melanoma - Pipeline Review, H1 2018, provides an overview of the Melanoma (Oncology) pipeline landscape.

Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Melanoma - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 19, 116, 125, 1, 9, 217, 30 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 18, 13, 1, 73 and 10 molecules, respectively.

Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Melanoma - Overview
Melanoma - Therapeutics Development
Melanoma - Therapeutics Assessment
Melanoma - Companies Involved in Therapeutics Development
Melanoma - Drug Profiles
Melanoma - Dormant Projects
Melanoma - Discontinued Products
Melanoma - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Melanoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Melanoma - Pipeline by 4D Pharma PLC, H1 2018
Melanoma - Pipeline by 4P-Pharma SAS, H1 2018
Melanoma - Pipeline by 4SC AG, H1 2018
Melanoma - Pipeline by AB Science SA, H1 2018
Melanoma - Pipeline by AbbVie Inc, H1 2018
Melanoma - Pipeline by Abivax SA, H1 2018
Melanoma - Pipeline by Adaptimmune Therapeutics Plc, H1 2018
Melanoma - Pipeline by Aduro BioTech Inc, H1 2018
Melanoma - Pipeline by Advenchen Laboratories LLC, H1 2018
Melanoma - Pipeline by Aeglea BioTherapeutics Inc, H1 2018
Melanoma - Pipeline by Affichem SA, H1 2018
Melanoma - Pipeline by AGV Discovery SAS, H1 2018
Melanoma - Pipeline by AIMM Therapeutics BV, H1 2018
Melanoma - Pipeline by Alkermes Plc, H1 2018
Melanoma - Pipeline by Allergy Therapeutics Plc, H1 2018
Melanoma - Pipeline by Alligator Bioscience AB, H1 2018
Melanoma - Pipeline by Altor BioScience Corp, H1 2018
Melanoma - Pipeline by Amgen Inc, H1 2018
Melanoma - Pipeline by Angimmune LLC, H1 2018
Melanoma - Pipeline by Antibe Therapeutics Inc, H1 2018
Melanoma - Pipeline by Antigen Express Inc, H1 2018
Melanoma - Pipeline by APEIRON Biologics AG, H1 2018
Melanoma - Pipeline by Apexigen Inc, H1 2018
Melanoma - Pipeline by Aphios Corp, H1 2018
Melanoma - Pipeline by Aposense Ltd, H1 2018
Melanoma - Pipeline by Aprea AB, H1 2018
Melanoma - Pipeline by Aptose Biosciences Inc, H1 2018
Melanoma - Pipeline by Arcus Biosciences Inc, H1 2018
Melanoma - Pipeline by ARMO Biosciences Inc, H1 2018
Melanoma - Pipeline by Array BioPharma Inc, H1 2018
Melanoma - Pipeline by Asana BioSciences LLC, H1 2018
Melanoma - Pipeline by Astex Pharmaceuticals Inc, H1 2018
Melanoma - Pipeline by Atreca Inc, H1 2018
Melanoma - Pipeline by aTyr Pharma Inc, H1 2018
Melanoma - Pipeline by Aurigene Discovery Technologies Ltd, H1 2018
Melanoma - Pipeline by Autolus Ltd, H1 2018
Melanoma - Pipeline by Basilea Pharmaceutica Ltd, H1 2018
Melanoma - Pipeline by Batu Biologics Inc, H1 2018
Melanoma - Pipeline by Bayer AG, H1 2018
Melanoma - Pipeline by BeiGene Ltd, H1 2018
Melanoma - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1 2018
Melanoma - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018
Melanoma - Pipeline by BerGenBio ASA, H1 2018
Melanoma - Pipeline by Bio-Cancer Treatment International Ltd, H1 2018
Melanoma - Pipeline by Biocad, H1 2018
Melanoma - Pipeline by Biogazelle NV, H1 2018
Melanoma - Pipeline by Biohaven Pharmaceutical Holding Company Ltd, H1 2018
Melanoma - Pipeline by BioLineRx Ltd, H1 2018
Melanoma - Pipeline by Bionomics Ltd, H1 2018
Melanoma - Pipeline by BioNTech AG, H1 2018
Melanoma - Pipeline by Biothera Pharmaceutical Inc, H1 2018
Melanoma - Pipeline by Biovista Inc, H1 2018
Melanoma - Pipeline by Boehringer Ingelheim GmbH, H1 2018
Melanoma - Pipeline by Boston Biomedical Inc, H1 2018
Melanoma - Pipeline by BrightPath Biotherapeutics Co Ltd, H1 2018
Melanoma - Pipeline by Bristol-Myers Squibb Co, H1 2018
Melanoma - Pipeline by Calithera Biosciences Inc, H1 2018
Melanoma - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Melanoma - Pipeline by CBT Pharmaceuticals Inc, H1 2018
Melanoma - Pipeline by CCRP Therapeutics GmbH, H1 2018
Melanoma - Pipeline by Celgene Corp, H1 2018
Melanoma - Pipeline by Celldex Therapeutics Inc, H1 2018
Melanoma - Pipeline by Cellestia Biotech AG, H1 2018
List of Figures
Number of Products under Development for Melanoma, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Top 10 Molecule Types, H1 2018
Number of Products by Stage and Top 10 Molecule Types, H1 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report